

PA Health & Wellness Pharmacy and Therapeutics Committee Meeting Minutes
1700 Bent Creek Blvd, Suite 200, Mechanicsburg, PA 17050

Wednesday, October 8, 2025 – 12:00 PM – 1:30 PM

Present: Jason Skaria, PharmD, Jill Schaeffer, RN, Michelle Bennett, RPh, Dr. Venkateswara Davuluri, Dr. Kolin Good, Dr. John Shand, Grace Robinson (CHC Participant)

Absent: Dr. Craig Butler, Dr. Chris Squillaro

Non-Voting Members: Shalyn Kline (Pharmacy), Evan Sebastian (Pharmacy), George Kimbrow (Clinical Policy Coodinator), Heather Clarke (Director of Case Management).

Call to Order: The PA Health & Wellness Pharmacy and Therapeutics Committee meeting called to order at 12:03 PM.

Adjourned: The PA Health & Wellness Pharmacy and Therapeutics Committee meeting was adjourned at 12:23 PM.

Next Meeting: Wednesday, January 14, 2026 – 12:00 PM

Submitted By: Shalyn Kline (PHW Pharmacy)

Committee Chair: *Shalyn Kline*

Date: 01/14/2026

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

Agenda Item	Discussion/Recommendation	Action	Next Steps	Owner
I. Introduction & Call to Order	Jason called the PA Health & Wellness Pharmacy & Therapeutics Committee meeting to order at 12:03 PM.	Meeting Called to Order		Jason Skaria
A. Introductions	No new introductions			Jason Skaria
B. Announcements	Jason reminded all that 75% attendance is required for all voting members to remain as active committee members.	No action required or taken.		Jason Skaria
C. Explanation of the Review and Approval Process	i. Voting and vote totals ii. Tie breaker iii. Pennsylvania's Review and Approval Process	No action required or taken.		Jason Skaria
D. Charter Review	The committee charter was reviewed with the committee members, with the addition of the CHIP (Children's Health Insurance Program) line of business.	No action required or taken.		Jason Skaria
II. Approval of Meeting Minutes	A vote was taken for the approval of the minutes from Q3_2025. No objections were made. Motion to approve: Dr. John Shand Second motion to approve: Dr. Kolin Good	Adoption of Q3_2025 Meeting Minutes recorded as approved		Shalyn Kline
III. Old Business	No old business	No action required or taken.		
A. Policy Submission Status	There are 28 outstanding clinical policies awaiting approval.	No action required or taken.		Shalyn Kline
IV. New Business				

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

A. Provider Education	<p>A vote was taken for the approval of the EVALI (E-cigarette or Vaping-Associated Lung Injury) provider education. No objections were made.</p> <p>Motion to approve: Michelle Bennett, RPh Second motion to approve: Dr. John Shand</p>	The provider education was Committee approved.		Shalyn Kline
B. FDA Updates	This is informational only and addresses recalls, new drugs, etc. No vote necessary.	Informational		Shalyn Kline
C. Guidelines – Drug Coverage Criteria	<p>Review on Combined Summary Table for summary of revisions. A vote was taken for the approval of 5 new policies created, 33 policies had clinically significant change, 51 policies with no significant changes and 2 policies being retired for Medicaid.</p> <p>No objections, concerns or comments were made.</p> <p>Motion to approve: Dr. Kolin Good Second motion to approve: Dr. John Shand</p> <p>A vote was taken for 848 policies for CHIP line of business.</p> <p>Motion to approve: Dr. John Shand Second motion to approve: Dr. Kolin Good</p>	The policy revisions were Committee approved.		Shalyn Kline
D. Additional Drug Lists and Policies and Procedures	<p>A vote was taken for the approval of the CHIP formulary</p> <p>Motion to approve: Dr. John Shand Second motion to approve: Dr. Kolin Good</p> <p>A vote was taken for the approval of the 15 Pharmacy Policy & Procedures.</p> <p>Motion to approve: Dr. John Shand Second motion to approve: Dr. Kolin Good</p>	The policy and drug lists revisions were Committee approved.		Shalyn Kline

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

E. Highlights of New Medications/ Significant Changes	<p>Shalyn reviewed Keytruda Qlex, a new formulation of Keytruda that can be administered in a providers office in as little as 1 minute. Shalyn reviewed Brinsupri (brensocatib) for non-cystic fibrosis bronchiectasis for 12 years and older. She reviewed common dermatological, gingival and periodontal side effects.</p> <p>Shalyn also reviewed that Xifaxan is no longer covered by Medicaid, but the state does allow for the approval of Xifaxan 200mg for hepatic encephalopathy after the failure of Lactulose with prior authorization</p>	No action required or taken.		Shalyn Kline
F. Complaints and Grievances Review	<p>Shalyn stated that there was 1 determination upheld and 6 overturned and 0 withdrawn during pre-grievance. 1 of the 7 determinations were for opioids. 1 of the 7 determinations were for GLP-1 receptor agonists.</p> <p>Dr Shand asked if this was a common number of complaints and grievances.</p> <p>Shalyn stated recently we have had 4 to 7 a quarter. It was higher in the past but looked for opportunities to improve and have seen less grievances.</p>	No action required or taken.		Shalyn Kline
H. Drug Utilization Review	<p>Evan presented the drug utilization review, noted the numbers are for Q3 2025.</p> <p>For quarter 3 there was over 8,000 drug utilization review outreaches and about 18% have been resolved.</p> <p>FWA – There were 38 Participants reviewed with 90 Morphine Milligram Equivalent (MME) or more. No issues were found. Three Participants were identified with three or more practices/hospitals prescribing opioids.</p> <p>Dr. John Shand asked how we identify members with over 90MME. Evan is able to run a report based off claims and does a deep dive from there. Dr. Shand asked about return communication from Providers regarding the MME fax communication. Evan advised</p>	No action required or taken.	Evan will communicate with Dr. Shand on how the loop is closed to ensure the provider has received the faxed information, if existing.	Shalyn Kline

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).

	there is no expectation or return communication as we prefer not to seem to give limitations to prescriptive practice.			
I. PBM Oversight	<p>Prior Authorization Audits:</p> <ul style="list-style-type: none"> July – 94.44% passed August – 97.58% passed September – 98.91% passed <p>Call Center:</p> <ul style="list-style-type: none"> July – 872 – 100% within TAT August – 868 – 100% within TAT September – data not finalized 	No action required or taken.		Jason Skaria
L. Open Forum	Dr. John Shand asked what we have seen for the CHIP population. Shalyn clarified that our CHIP line of business is set to launch on 1/1/2026. PHW is expecting a small population in the beginning and hoping for it to grow within the first year.	No action required or taken.		Shalyn Kline
Adjournment	<p>The meeting was adjourned at 12:23 pm</p> <p>Jason asked for a motion to adjourn.</p> <p>Motion to adjourn: Dr. John Shand</p> <p>Second motion to adjourn: Dr. Venkateswara Davuluri</p>	Meeting adjourned		Jason Skaria

CONFIDENTIAL Notice: This document comprises the confidential investigations, proceedings, and/or records of a medical review Committee and is not subject to discovery or introduction into evidence in any civil or administrative action. This document contains information deemed confidential by the health care quality improvement act of 1986 (42 U.S.C.S. §1137 (b)).